Substituted chroman derivatives, medicaments and use in therapy

Details Substituted chroman derivatives, medicaments and use in therapy Substituted chroman derivatives, medicaments and use in therapy

2005-09-21

2009-10-13

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07601855

ABSTRACT:
Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

REFERENCES:
patent: 0470310 (1992-12-01), None
patent: 1433013 (1976-04-01), None
patent: 94/08986 (1994-04-01), None
patent: 94/20099 (1994-09-01), None
patent: 96/21442 (1996-07-01), None
patent: 96/21443 (1996-07-01), None
patent: 96/21444 (1996-07-01), None
patent: 96/22091 (1996-07-01), None
patent: 96/22092 (1996-07-01), None
patent: 96/22093 (1996-07-01), None
patent: 97/25035 (1997-07-01), None
patent: 97/25036 (1997-07-01), None
patent: 98/02154 (1998-01-01), None
patent: 98/02156 (1998-01-01), None
patent: 98/17662 (1998-04-01), None
patent: 98/18770 (1998-05-01), None
patent: 98/18771 (1998-05-01), None
patent: 98/18778 (1998-05-01), None
patent: 98/25916 (1998-06-01), None
patent: 98/32437 (1998-07-01), None
patent: 98/33499 (1998-08-01), None
patent: 98/33500 (1998-08-01), None
patent: 99/49862 (1999-10-01), None
patent: 99/55898 (1999-11-01), None
patent: 99/63974 (1999-12-01), None
patent: 99/65893 (1999-12-01), None
patent: 01/17986 (2001-03-01), None
patent: 01/26651 (2001-04-01), None
patent: 01/54699 (2001-08-01), None
patent: 02/02548 (2002-01-01), None
patent: 02/059113 (2002-08-01), None
patent: WO 02/059113 (2002-08-01), None
patent: 03/016270 (2003-02-01), None
patent: 03/035635 (2003-05-01), None
patent: 03/063859 (2003-08-01), None
patent: 03/086386 (2003-10-01), None
patent: 2004/030662 (2004-04-01), None
patent: 2005/049008 (2005-06-01), None
patent: 2006/032085 (2006-03-01), None
patent: 2006/032086 (2006-03-01), None
Paul S. Bury et al., Bioorganic & Medicinal Chemistry, 10 (2002) 125-145. p. 126, 127 and 128.
B. Aggarwal, et al., “From chemoprevention to chemotherapy: common targets and common goals”, Expert Opin. Investig. Drugs, (2004), vol. 13(10): pp. 1327-1338.
T. Akimoto, et al., “Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways”, Int. J. Radiation Oncology Biol. Phys., vol. 50, No. 1, pp. 195-201, 2001.
F. Bellisarii et al., “Tumor necrosis factor-α and cardiovascular diseases”, Ital Heart J 2001; vol. 2(6): pp. 408-417.
B. Bradbury, “Some oestrogenic 4-phenyl-substituted isoflav-3-ENS”, Australian Journal of Chemistry, vol. 6, 1953, pp. 447-449.
P. Bury, et al., “Synthesis and pharmacological evaluation of novelcis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor”, Bioorganic & Medicinal Chemistry, vol. 10, (2002), pp. 125-145.
A. Constantinou, et al., “Phenoxodiol, a novel isofavone derivative, inhibits dimethylbenz[a]anthracene(DMBA)-induced mammary carcinogenesis in female Sprague—Dawley rats”, European Journal of Cancer, vol. 39, (2003), pp. 1012-1018.
A. Constantinou, et al. “Phenoxodiol (2H-1-Benzopyran-7-0,1,3-(4-hydroxyphenyl), a Novel Isoflavone Derivative, Inhibits DNA Topoisomerase II by Stabilizing the Cleavable Complex”, Anticancer Research, vol. 22, pp. 2581-2586, (2002).
T. Dorai, et al., “Role of chemopreventive agents in cancer therapy” Cancer Letters, vol. 215, (2004), pp. 129-140.
J. Gamble, et al., “Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects”, Int. J. Cancer, vol. 118, pp. 2412-2420, (2006).
P. Hersey, et al., “How melanoma cells evade trail-induced apoptosis” Nov. 2001, vol. 1, pp. 142-150.
Hem Chandra Jha, et al., “Carbon -13- chemical shift assignments of chromones and isoflavones”, Can, J. Chem., vol. 58, pp. 1211-1219, (1980).
Y. Kakeji, et al., “Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents” Investigational New Drugs, vol. 15, pp. 39-48, 1997.
M. Kamsteeg, et al., “Phenoxodiol—an isoflavone analog- induces apoptosis in chemoresistant ovarian cancer cells” Oncogene, (2003), vol. 22, pp. 2611-2620.
B. Kang, et al., “Scientific Analysis of Formulation Theory of Chungpesagan- tang; In vitro Cytotoxicity of Cisplatin Combined with Chungpesagan-tang”, Natural Product Sciences, vol. 6(4), pp. 165-169, (2000).
S. Khoshyomn, et al., “Synergistic Action of Genistein and Ciplatin on Growth Inhibition and Cytotoxicity of Human Medulloblastoma Cells”; Pediatr. Neurosurg, 2000, vol. 33, pp. 123-131.
Y. Li, et al., “Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-KB in BxPC-3 Pancreatic Cancer Cell Line”, Pancreas, vol. 28, No. 4, pp. e90-e95.
C. McDonnell, et al., “Improvement in Efficacy of Chemoradiotherapy by Addition of and Antiangiogenic Agent in a Murine Tumor Model”, Journal of Surgical Research, Vo. 116, pp. 19-23, (2004).
R. Micheli, et al., “Coumestro, Plant Phenolics, and Synthetic Estrogens: a Correlation of Structure and Activity”, Journal of Medicinal and Pharmaceutical Chemistry, vol. 5, 1962, pp. 321-335.
Nakata, E. et al., “C225 Antiepidermal Growth Factor Receptor Antibody Enhances the Efficacy of Docetaxel Chemoradiotherapy”, Int. J. Radiation Oncology Biol. Phys., vol. 59, No. 4, pp. 1163-1173, 2004.
P. O'Dwyer, et al., “Antitumor Activity and Biochemical Effects of Aphidicolin Glycinate(NSC 303812) Alone and in Combination with Cisplatin in Vivo”; Cancer Research, vol. 54, pp. 724-729, Feb. 1, 1994.
M. O'Neill, et al., “Inducible Isoflavonoids from the Lima Bean,Phaseolus lunatus”, Phytochemistry, vol. 25, No. 6, pp. 1315-1322, 1986.
M. Rafi, et al., “Modulation of bcl-2 and Cytotoxicity by Licochalcone-A, a Novel Estrogenic Flavonoid”, Anticancer Research, vol. 20, pp. 2653-2658, (2000).
M. Ravindranath, et al., “Anticancer Therapeutic Potential of Soy Isoflavone, Genistein”, Complementary and Alternative Approaches to Biomedicine, edited by Edwin L. Cooper and Nobuo Yamaguchi. Kluwer Academic/Plenum Publishers, 2004, p. 121.
S. Sepulveda-Boza, et al., “The preparation of new isoflavones”, Synthetic Communications, vol. 3(12), pp. 1933-1940, (2001).
P. Szlosarek, et al., “Tumour necrosis factor α: a potential target for the therapy of solid tumours”, The Lancet Oncology, vol. 4, pp. 565-573, Sep. 2003.
S. Tamura, et al., “Genistein Enhances the Cisplatin-Induced Inhibition of Cell Growth and Apoptosis in Human Malignant Melanoma Cells”; Pigment Cell Res., vol. 16, pp. 470-476, 2003.
P. Todorov, et al., “Role of a proteolysis-inducing factor(PIF) in a cachexia induced by a human melanoma(G361)”, British Journal of Cancer, (1999), vol. 80(11), pp. 1734-1737.
Verma, P. et al., “Smooth Conversion of 3,4-Diarylcoumarins and 3,4,5- Triaryl-2(5H)-furanones to 2H-Chromene and 2,5-Dihydrofuran Derivatives with Dimethyl Sulfide-Borane Complex”, Synthesis, vol. (1), 1988, pp. 68-70.
W. Lei, et al., “Enhancement of Chemosensitivity and Programmed Cell death by Tyrosine Kinase Inhibitors Correlates with EGFR Expression in Non-Small Cell Lung Cancer Cells”, Anticancer Research, vol. 19, pp. 221-228, (1989).
O. Wolfbeis, et al., “The Absorption and Fluorescence of Isoflavones and the Effect of Shift Reagents”, Z. Naturforsch, vol. 39b, pp. 238-243, (1984); received Sep. 23, 1983.
E. Zyner, et al., “Platinum(II) and palladium(II) N,0-Chelates with substituted flavanone containing ligangs”, Acta Polonia Pharamaceutica, Drug Research, vol. 56, No. 2, pp. 159-167, 1999.
E. Zyner, et al., “Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation”, Pharmazie, 54, (1999), 12, pp. 945-946.
B. Abegaz, et al., “Isofl

Affiliated with

Also associated with

Rating

Substituted chroman derivatives, medicaments and use in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted chroman derivatives, medicaments and use in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted chroman derivatives, medicaments and use in therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4077964